{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:10:37Z","timestamp":1768972237154,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T00:00:00Z","timestamp":1638748800000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Abnormal expression patterns of microRNAs (miRs) play an important role in the development and progression of malignancy. Identification of the clinical significance and prognostic value of these small molecules in chronic lymphocytic leukemia (CLL); a disease of heterogeneous biological landscape and clinical course, has always been of tremendous translational value.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>To evaluate the prognostic value of microRNA17-92 cluster members in Egyptian CLL patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The expression levels of miR17-92 cluster members were evaluated by qRT-PCR, including miR17, miR18a, miR19a, miR19b-1, miR20a, and miR92a-1. Other investigations included serum LDH, serum \u03b22 microglobulin (\u03b22M), CD38 and ZAP70 expression by flow cytometry, fluorescence in situ hybridization (FISH) for 17p deletion, and imaging studies (computerized tomography (CT) scans of neck, chest, abdomen, and pelvis or PET-CT scans).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overexpression of all members of the miRNA17-92 cluster was detected in CLL patients compared to controls (<jats:italic>p<\/jats:italic>\u2009=\u2009\u2009&lt;\u20090.001 for all miRs while <jats:italic>p<\/jats:italic>\u2009=\u20090.01 for miR19b-1). A significant positive correlation between Hb and miR17 and a significant negative correlation between Hb and miR19b-1 were observed (<jats:italic>p<\/jats:italic>\u2009=\u20090.041, 0.017 respectively). A statistically significant positive correlation between miR19b-1 expression and each of the WBCs and absolute lymphocytic count (ALC) was detected (<jats:italic>p<\/jats:italic>\u2009=\u20090.023, 0.022 respectively). Moreover, a statistically significant relation between miR19b-1 expression and advanced Binet stages was also found (<jats:italic>p<\/jats:italic>\u2009=\u20090.05). Regarding miR18a, a statistically significant positive correlation with LDH level was found (<jats:italic>p<\/jats:italic>\u2009=\u20090.003). We also found a significant positive correlation between miR92a-1 and \u03b22M level (<jats:italic>p<\/jats:italic>\u2009=\u20090.005), as well as a significant relation between miR17 and negative CD38 expression (<jats:italic>p<\/jats:italic>\u2009=\u20090.034). However, no significant relationships between any of studied miRNA expression levels and 17p deletion or response to treatment were observed. Patients who expressed miR19b-1 were significantly indicated to start therapy at diagnosis (<jats:italic>p<\/jats:italic>\u2009=\u20090.05). The overall survival of CLL patients included in our study was 90.2% after 1\u00a0year from the time of diagnosis. Patients with high expression of miR19a had better OS than those with low expression (<jats:italic>p<\/jats:italic>\u2009=\u20090.04).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Overexpression of all members of the miR17-92 cluster was detected in Egyptian CLL patients. MiR18a, miR19b-1, and miR92a-1 also have an adverse prognostic value while miR17 can be considered a good prognostic marker. High expression of miR19a is associated with better OS.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s43046-021-00097-x","type":"journal-article","created":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T00:03:56Z","timestamp":1638749036000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Prognostic significance of microRNA 17\u201392 cluster expression in Egyptian chronic lymphocytic leukemia patients"],"prefix":"10.1186","volume":"33","author":[{"given":"M. M.","family":"Khalifa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. E.","family":"Zaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. A.","family":"Nazier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"Moussa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Abdel","family":"Haleem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"Rabie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. R.","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,6]]},"reference":[{"key":"97_CR1","doi-asserted-by":"publisher","first-page":"16096","DOI":"10.1038\/nrdp.2016.96","volume":"3","author":"TJ Kipps","year":"2017","unstructured":"Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, et al. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017;3:16096.","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"97_CR2","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1002\/ajh.25595","volume":"94","author":"M Hallek","year":"2019","unstructured":"Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol. 2019;94(11):1266\u201387.","journal-title":"Am J Hematol"},{"issue":"4","key":"97_CR3","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.bjhh.2016.07.004","volume":"38","author":"CA Rodrigues","year":"2016","unstructured":"Rodrigues CA, Goncalves MV, Ikoma MR, Lorand-Metze I, Pereira AD, Farias DL, et al. Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia. Rev Bras Hematol Hemoter. 2016;38(4):346\u201357.","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"25","key":"97_CR4","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745\u201360.","journal-title":"Blood"},{"issue":"4","key":"97_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/cancers12040894","volume":"12","author":"JA Cohen","year":"2020","unstructured":"Cohen JA, Bomben R, Pozzo F, Tissino E, Harzschel A, Hartmann TN, et al. An updated perspective on current prognostic and predictive biomarkers in chronic lymphocytic leukemia in the context of chemoimmunotherapy and novel targeted therapy. Cancers. 2020;12(4):17.","journal-title":"Cancers"},{"issue":"1","key":"97_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1182\/blood-2018-01-785998","volume":"132","author":"JG Gribben","year":"2018","unstructured":"Gribben JG. How and when I do allogeneic transplant in CLL. Blood. 2018;132(1):31\u20139.","journal-title":"Blood"},{"issue":"5","key":"97_CR7","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1182\/blood-2018-12-889113","volume":"133","author":"DM Stephens","year":"2019","unstructured":"Stephens DM. Highs and lows of minimal residual disease in CLL. Blood. 2019;133(5):386\u20138.","journal-title":"Blood"},{"issue":"1","key":"97_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4331\/wjbc.v8.i1.45","volume":"8","author":"S Oliveto","year":"2017","unstructured":"Oliveto S, Mancino M, Manfrini N, Biffo S. Role of microRNAs in translation regulation and cancer. World J Biol Chem. 2017;8(1):45\u201356.","journal-title":"World J Biol Chem"},{"key":"97_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-015-0112-x","volume":"8","author":"V Balatti","year":"2015","unstructured":"Balatti V, Pekarky Y, Croce CM. Role of microRNA in chronic lymphocytic leukemia onset and progression. J Hematol Oncol. 2015;8:12.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"97_CR10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fmed.2015.00064","volume":"8","author":"CS Fuziwara","year":"2015","unstructured":"Fuziwara CS, Kimura ET. Insights into regulation of the miR-17\u201392 cluster of miRNAs in cancer. Front Med(Lausanne). 2015;8(2):64. https:\/\/doi.org\/10.3389\/fmed.2015.00064.","journal-title":"Front Med(Lausanne)"},{"issue":"23","key":"97_CR11","doi-asserted-by":"publisher","first-page":"19381","DOI":"10.18632\/oncotarget.4574","volume":"6","author":"M Dal Bo","year":"2015","unstructured":"Dal Bo M, Bomben R, Hernandez L, Gattei V. The MYC\/miR-17-92 axis in lymphoproliferative disorders: a common pathway with therapeutic potential. Oncotarget. 2015;6(23):19381\u201392.","journal-title":"Oncotarget"},{"issue":"12","key":"97_CR12","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1038\/cdd.2013.125","volume":"20","author":"E Mogilyansky","year":"2013","unstructured":"Mogilyansky E, Rigoutsos I. The miR-17\/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ. 2013;20(12):1603\u201314.","journal-title":"Cell Death Differ"},{"issue":"1","key":"97_CR13","doi-asserted-by":"publisher","first-page":"8375","DOI":"10.1038\/s41598-017-08349-4","volume":"7","author":"K Zhang","year":"2017","unstructured":"Zhang K, Zhang L, Zhang M, Zhang Y, Fan D, Jiang J, et al. Prognostic value of high-expression of miR-17-92 cluster in various tumors: evidence from a meta-analysis. Sci Rep. 2017;7(1):8375.","journal-title":"Sci Rep"},{"issue":"3","key":"97_CR14","first-page":"2459","volume":"20","author":"S Yan","year":"2019","unstructured":"Yan S, Jia C, Quan L, Zhao L, Tian Y, Liu A. Significance of the microRNA17-92 gene cluster expressed in B cell nonHodgkin\u2019s lymphoma. Mol Med Rep. 2019;20(3):2459\u201367.","journal-title":"Mol Med Rep"},{"issue":"21","key":"97_CR15","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1182\/blood.V116.21.2727.2727","volume":"116","author":"RE Culpin","year":"2010","unstructured":"Culpin RE, Pearce K, Bailey JR, Sunter NJ, Pointon JC, Proctor SJ, et al. Mature microRNAs mir-18, -19a, -19b, -17-5p and -92 of the mir-17-92 cluster predict for treatment free survival in patients with chronic lymphocytic leukaemia. Blood. 2010;116(21):2727.","journal-title":"Blood"},{"issue":"7","key":"97_CR16","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1038\/leu.2012.44","volume":"26","author":"R Bomben","year":"2012","unstructured":"Bomben R, Gobessi S, Dal Bo M, Volinia S, Marconi D, Tissino E, et al. The miR-17\u223c92 family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. Leukemia. 2012;26(7):1584\u201393.","journal-title":"Leukemia"},{"key":"97_CR17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2147\/JBM.S230842","volume":"11","author":"E Farzadfard","year":"2020","unstructured":"Farzadfard E, Kalantari T, Tamaddon G. Serum expression of seven microRNAs in chronic lymphocytic leukemia patients. J Blood Med. 2020;11:97\u2013102.","journal-title":"J Blood Med"},{"issue":"24","key":"97_CR18","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1101\/gad.1861409","volume":"23","author":"V Olive","year":"2009","unstructured":"Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, Cordon-Cardo C, et al. MiR-19 is a key oncogenic component of mir-17-92. Genes Dev. 2009;23(24):2839\u201349.","journal-title":"Genes Dev"},{"issue":"9","key":"97_CR19","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.3109\/10428194.2012.763123","volume":"54","author":"G Ferrer","year":"2013","unstructured":"Ferrer G, Navarro A, Hodgson K, Aymerich M, Pereira A, Baumann T, et al. MicroRNA expression in chronic lymphocytic leukemia developing autoimmune hemolytic anemia. Leuk Lymphoma. 2013;54(9):2016\u201322.","journal-title":"Leuk Lymphoma"},{"issue":"16","key":"97_CR20","doi-asserted-by":"publisher","first-page":"6573","DOI":"10.1073\/pnas.1019557108","volume":"108","author":"E Moussay","year":"2011","unstructured":"Moussay E, Wang K, Cho JH, van Moer K, Pierson S, Paggetti J, et al. MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2011;108(16):6573\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"97_CR21","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1080\/10428194.2018.1461861","volume":"60","author":"SG Papageorgiou","year":"2019","unstructured":"Papageorgiou SG, Diamantopoulos MA, Kontos CK, Bouchla A, Vasilatou D, Bazani E, et al. MicroRNA-92a-3p overexpression in peripheral blood mononuclear cells is an independent predictor of prolonged overall survival of patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2019;60(3):658\u201367.","journal-title":"Leuk Lymphoma"},{"issue":"19","key":"97_CR22","doi-asserted-by":"publisher","first-page":"4486","DOI":"10.1182\/blood-2011-09-378687","volume":"119","author":"Y Li","year":"2012","unstructured":"Li Y, Vecchiarelli-Federico LM, Li YJ, Egan SE, Spaner D, Hough MR, et al. The miR-17-92 cluster expands multipotent hematopoietic progenitors whereas imbalanced expression of its individual oncogenic miRNAs promotes leukemia in mice. Blood. 2012;119(19):4486\u201398.","journal-title":"Blood"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-021-00097-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-021-00097-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-021-00097-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T00:06:35Z","timestamp":1638749195000},"score":1,"resource":{"primary":{"URL":"https:\/\/jenci.springeropen.com\/articles\/10.1186\/s43046-021-00097-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["97"],"URL":"https:\/\/doi.org\/10.1186\/s43046-021-00097-x","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"6 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all study subjects. Also, approval of the Research Ethics Committee of Alexandria Faculty of Medicine was obtained prior to the study. All procedures performed in our study were in accordance with the ethical standards of our institution and national and with the 1975 Helsinki declaration as revised in 2008.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}